Zhangyi Luo

703 total citations
22 papers, 555 citations indexed

About

Zhangyi Luo is a scholar working on Molecular Biology, Immunology and Biomedical Engineering. According to data from OpenAlex, Zhangyi Luo has authored 22 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Immunology and 7 papers in Biomedical Engineering. Recurrent topics in Zhangyi Luo's work include Nanoplatforms for cancer theranostics (7 papers), RNA Interference and Gene Delivery (6 papers) and Nanoparticle-Based Drug Delivery (5 papers). Zhangyi Luo is often cited by papers focused on Nanoplatforms for cancer theranostics (7 papers), RNA Interference and Gene Delivery (6 papers) and Nanoparticle-Based Drug Delivery (5 papers). Zhangyi Luo collaborates with scholars based in United States and China. Zhangyi Luo's co-authors include Song Li, Jingjing Sun, Ziqian Zhang, Haozhe Huang, Zhuoya Wan, Yuang Chen, Yixian Huang, Jieni Xu, Binfeng Lu and Bei Zhang and has published in prestigious journals such as Nature Communications, Nature Nanotechnology and Biomaterials.

In The Last Decade

Zhangyi Luo

22 papers receiving 550 citations

Peers

Zhangyi Luo
Shufang Shen China
Mark Prytyskach United States
Zhuoya Wan United States
Minglu Zhou China
Prajna Mishra India
Lingfei Han China
Sujan Kumar Mondal United States
Kun Tu China
Chunyu Xia China
Weiqiang Jing China
Shufang Shen China
Zhangyi Luo
Citations per year, relative to Zhangyi Luo Zhangyi Luo (= 1×) peers Shufang Shen

Countries citing papers authored by Zhangyi Luo

Since Specialization
Citations

This map shows the geographic impact of Zhangyi Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhangyi Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhangyi Luo more than expected).

Fields of papers citing papers by Zhangyi Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhangyi Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhangyi Luo. The network helps show where Zhangyi Luo may publish in the future.

Co-authorship network of co-authors of Zhangyi Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Zhangyi Luo. A scholar is included among the top collaborators of Zhangyi Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhangyi Luo. Zhangyi Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luo, Zhangyi, Chien‐Yu Chen, & Song Li. (2025). Improving Tumor Targeting and Penetration for Nanoparticle‐Mediated Cancer Therapy. Small Methods. 9(8). e2401860–e2401860. 8 indexed citations
2.
Huang, Haozhe, Yixian Huang, Beihong Ji, et al.. (2025). Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance. Nature Communications. 16(1). 4176–4176. 3 indexed citations
3.
Luo, Zhangyi, Yixian Huang, Neelu Batra, et al.. (2024). Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy. Nature Communications. 15(1). 255–255. 30 indexed citations
4.
Luo, Zhangyi, Yixian Huang, Shangyu Chen, et al.. (2024). Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer. Cancer Letters. 604. 217268–217268. 4 indexed citations
5.
Chen, Yuang, Chien‐Yu Chen, Haozhe Huang, et al.. (2024). Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment. Journal of Controlled Release. 370. 479–489. 5 indexed citations
6.
Luo, Zhangyi, Zhuoya Wan, Pengfei Ren, et al.. (2024). In Situ Formation of Fibronectin‐Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy. Advanced Science. 11(19). e2307940–e2307940. 11 indexed citations
7.
Huang, Haozhe, Beihong Ji, Yixian Huang, et al.. (2024). Advanced Hierarchical Computational Modeling‐Based Rational Development of Platinum (II) Nanocomplex to Improve Lung Cancer Therapy. Advanced Functional Materials. 35(7). 4 indexed citations
8.
Zhang, Ziqian, Zhangyi Luo, Haozhe Huang, et al.. (2024). YAP/TAZ Inhibitor-Based Drug Delivery System for Selective Tumor Accumulation and Cancer Combination Therapy. Biomacromolecules. 26(1). 266–278. 1 indexed citations
9.
Luo, Zhangyi, Katherine M. Eichinger, Anju Zhang, & Song Li. (2023). Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy. Cancer Letters. 575. 216396–216396. 33 indexed citations
10.
Zhang, Yue, Jiang Li, Yixian Huang, et al.. (2023). Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1. Theranostics. 13(2). 578–595. 14 indexed citations
11.
Chen, Yuang, Yixian Huang, Zhangyi Luo, et al.. (2022). Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nature Nanotechnology. 18(2). 193–204. 87 indexed citations
12.
Wan, Zhuoya, Haozhe Huang, Raymond E. West, et al.. (2022). Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier. Materials Today. 62. 33–50. 48 indexed citations
13.
Moharil, Pearl, Zhuoya Wan, Jiang Li, et al.. (2021). Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages. Acta Pharmaceutica Sinica B. 12(3). 1148–1162. 53 indexed citations
14.
Chen, Yuang, Yixian Huang, Haozhe Huang, et al.. (2021). Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination. Molecular Therapy — Nucleic Acids. 26. 594–602. 11 indexed citations
15.
Huang, Haozhe, Yixian Huang, Yuang Chen, et al.. (2021). A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. Biomaterials. 270. 120708–120708. 19 indexed citations
16.
Sun, Jingjing, Zhuoya Wan, Jieni Xu, et al.. (2020). Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer. Biomaterials. 269. 120629–120629. 41 indexed citations
17.
Luo, Zhangyi, Jieni Xu, Jingjing Sun, et al.. (2020). Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer. Acta Biomaterialia. 105. 239–252. 39 indexed citations
18.
Sun, Jingjing, Zhuoya Wan, Yichao Chen, et al.. (2020). Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. Acta Biomaterialia. 106. 289–300. 41 indexed citations
19.
Ma, Weina, Jingjing Sun, Jieni Xu, et al.. (2020). Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier. Theranostics. 10(6). 2463–2478. 39 indexed citations
20.
Weng, Jiang, Sheng Wang, Linjie Huang, Zhangyi Luo, & Gui Lu. (2015). Stereoselective synthesis of epoxyisoprostanes: an organocatalytic and “pot-economy” approach. Chemical Communications. 51(50). 10170–10173. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shufang Shen Breakdown of academic impact, for papers by Mark Prytyskach Breakdown of academic impact, for papers by Zhuoya Wan Breakdown of academic impact, for papers by Minglu Zhou Breakdown of academic impact, for papers by Prajna Mishra Breakdown of academic impact, for papers by Lingfei Han Breakdown of academic impact, for papers by Sujan Kumar Mondal Breakdown of academic impact, for papers by Kun Tu Breakdown of academic impact, for papers by Chunyu Xia Breakdown of academic impact, for papers by Weiqiang Jing
Rankless by CCL
2026